Around the world we are seeing a shortage of healthcare professionals, and health systems globally are under increased pressure brought on by the COVID-19 pandemic. One area of innovation that has been ramped up over recent years to support healthcare services and staff is clinical decision support (CDS).
In pathology, CDS is used to help pathologists sort through the barrage of patients to focus their attention where it is needed most, on complex or high-risk cases.
For years, Beamtree, an Australian Healthcare Technology Company has worked with healthcare organisations around the world to better capture, manage and leverage their human expertise to improve the performance of their business. In doing so, Beamtree have purpose built a CDS software (RippleDown) aimed at helping pathologists create an environment of continuous learning and awareness from existing, untapped data. Abbott, one of the largest healthcare companies in the world, with a vision to help communities live the best life they can, has seen the potential for CDS to help pathologists in healthcare organisations globally to provide patient focused outcomes.
It is this shared vision of improving care pathways for patients, that brought together the Beamtree and Abbott organisations, partnering under a global distribution agreement which has been in place since 2017. Distributing the Beamtree software (RippleDown) under the AlinIQ® CDS brand enables Beamtree access to global healthcare organisations (currently over 250 pathology and hospital organisations serviced by Abbott worldwide) while strengthening Abbott’s Digital Health portfolio to provide improvements to patient outcomes via clinical decision support. This model has enabled Abbott to further increase the value of the software through our medical liaison team. This team’s consultation engagement with our customers and pathologists helps further extend on the capability of the software, customising for specific disease-state recommendations and test appropriateness. AlinIQ® CDS, achieves this by providing accurate, reliable, and incisive decision support for pathology results and in turn, the requesting doctors. Data is gathered from disparate sources, including results from LIS and instrumentation, clinical documentations patient characteristics, geographical and/or environmental determinants.
AlinIQ® CDS then combines this data with rules-based insights built by clinical experts, to address dynamic changes occurring with the patient, while delivering consistent personalised reports in a timely manner. While the intended use is not to replace clinical judgement of a health professional, AlinIQ® CDS enhances laboratory reporting consistency and quality, delivering recommendations to a health professional - ultimately providing better healthcare outcomes.
Clinical expert users also have access to the system without a need to engage the IT team to alter rules through a feedback loop, therefore increasing and enhancing the expert scientific knowledge held in the system – while rapidly moving new evidence to practice.